TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20479948

Group type: EXPERIMENTAL
Intervention: Amlodipine/Atorvastatin (AML/ATO) + Therapeutic Lifestyle Changes (TLC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine (AML) + Therapeutic Lifestyle Changes (TLC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine/Atorvastatin (AML/ATO) + TLC
Number of subjects: 0
Study: 18829902

Group type: EXPERIMENTAL
Intervention: Postoperative lumbar corset for eight weeks full-time (experimental group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No postoperative corset (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postoperative lumbar corset (experimental group)
Number of subjects: 90
Study: 15925862

Group type: EXPERIMENTAL
Intervention: stacked ABR
Number of subjects: 54

Group type: COMPARATOR
Intervention: standard ABR measures (IT5 and I-V delay)
Number of subjects: 54
Study: 12489899

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg in the first week, 200 mg in the second week)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 15
Study: 10516393

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) administered at 12 and 24 hours of age
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no DEX treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both DEX and control groups
Number of subjects: 40
Study: 7793185

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IM 6 hourly postoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketorolac and Saline (both groups)
Number of subjects: 60
Study: 1934440

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonfiltered controls
Number of subjects: 50
Study: 6366135

Group type: EXPERIMENTAL
Intervention: L-phenylalanine mustard and 5-fluorouracil (PF) with tamoxifen (T)
Number of subjects: 1891

Group type: COMPARATOR
Intervention: L-phenylalanine mustard and 5-fluorouracil (PF)
Number of subjects: 1891
Study: 31037971

Group type: EXPERIMENTAL
Intervention: Paper version of HM-PRO
Number of subjects: 193

Group type: COMPARATOR
Intervention: Electronic version of HM-PRO
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Both versions of HM-PRO
Number of subjects: 193
Study: 30713751

Group type: EXPERIMENTAL
Intervention: Misoprostol only (Group 1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Single dose misoprostol + cervical Foley catheter (Group 2)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Foley catheter only (Group 3)
Number of subjects: 112
Study: 26466134

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Placebo (PLACEBO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 13
Study: 24148250

Group type: EXPERIMENTAL
Intervention: Snacks provided under stressed conditions
Number of subjects: 248

Group type: COMPARATOR
Intervention: Snacks provided under control conditions
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Short sleep duration
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: External stressor
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 248
Study: 18272912

Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, and bevacizumab with cetuximab (arm B)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Capecitabine, oxaliplatin, and bevacizumab without cetuximab (arm A)
Number of subjects: 755
Study: 15361383

Group type: EXPERIMENTAL
Intervention: 5 mg triamcinolone hexacetonide (0.25 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sterile 0.9% saline (0.25 ml)
Number of subjects: 40
Study: 11129665

Group type: COMPARATOR
Intervention: 30 minutes' physiotherapy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 60 minutes' physiotherapy
Number of subjects: 114
Study: 9531231

Group type: EXPERIMENTAL
Intervention: Alendronate sodium (initial dose 5 mg/d, increased to 10 mg/d at 24 months)
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2027
Study: 8232430

Group type: EXPERIMENTAL
Intervention: accelerated-dose tissue plasminogen activator (t-PA) with intravenous heparin
Number of subjects: 2431

Group type: COMPARATOR
Intervention: streptokinase with subcutaneous heparin
Number of subjects: 2431

Group type: COMPARATOR
Intervention: streptokinase with intravenous heparin
Number of subjects: 2431

Group type: COMPARATOR
Intervention: combination of both activators plus intravenous heparin
Number of subjects: 2431

Group type: COMPARATOR
Intervention: all treatment groups
Number of subjects: 2431

Group type: COMPARATOR
Intervention: patients with normal coronary flow at 90 minutes
Number of subjects: 2431

Group type: COMPARATOR
Intervention: patients with no flow at 90 minutes
Number of subjects: 2431
Study: 3501221

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 50
Study: 30818931

Group type: EXPERIMENTAL
Intervention: Rapid-enhanced group (40 μg at 0, 1, 2, 3 months; 60 μg at 4, 5, 6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rapid group (40 μg at 0, 1, 2, 3 months; 20 μg at 4, 5, 6 months)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Successful group (higher CTL and Th1 cell percentage increase)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-successful group (lower CTL and Th1 cell percentage increase)
Number of subjects: 120
Study: 28575232

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 101

Group type: COMPARATOR
Intervention: Statin nonusers
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 26769956

Group type: EXPERIMENTAL
Intervention: Horizontal bed rest in normobaric hypoxia (HBR)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Horizontal bed rest in normobaric normoxia (NBR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Horizontal bed rest combined with daily moderate intensity exercise (HAMB)
Number of subjects: 11
Study: 24120953

Group type: EXPERIMENTAL
Intervention: Vaniprevir (600 mg twice daily) with peginterferon and ribavirin for 24 weeks (n=16)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vaniprevir (600 mg twice daily) for 24 weeks with peginterferon and ribavirin for 48 weeks (n=14)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) with peginterferon and ribavirin for 48 weeks (n=15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vaniprevir (600 mg twice daily) with peginterferon and ribavirin for 48 weeks (n=15)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with peginterferon and ribavirin for 48 weeks (n=14, control)
Number of subjects: 60
Study: 22990394

Group type: EXPERIMENTAL
Intervention: Exercise group (encouraged to increase daily steps to 10,000)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not asked to change daily steps)
Number of subjects: 40
Study: 19460398

Group type: EXPERIMENTAL
Intervention: Interocularly matched target
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interocularly unmatched target
Number of subjects: 0
Study: 17490918

Group type: EXPERIMENTAL
Intervention: Physician‐delivered coronary heart disease risk evaluation and communication program
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1500
Study: 15154941

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11524308

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Acamprosate (1665‐1998 mg/day)
Number of subjects: 157
Study: 10174217

Group type: EXPERIMENTAL
Intervention: Teacher assisted by older pupils
Number of subjects: 243

Group type: COMPARATOR
Intervention: Teacher only
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Prior knowledge of resuscitation techniques
Number of subjects: 243
Study: 8178555

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3284133

Group type: EXPERIMENTAL
Intervention: Heparin/Dihydroergotamine (HDHE)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Heparin/Acenocoumarin (Hep/S)
Number of subjects: 212
Study: 29347996

Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate per day (4 over-encapsulated tablets)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 200
Study: 27057866

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 762

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 762
Study: 24482677

Group type: EXPERIMENTAL
Intervention: Sleep extension (468±88 days) with lifestyle modifications
Number of subjects: 121
Study: 24344672

Group type: EXPERIMENTAL
Intervention: High dose antibiotic impregnated cement (1 gram Clindamycin and 1 gram Gentamicin)
Number of subjects: 848

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 848
Study: 20664388

Group type: EXPERIMENTAL
Intervention: Vaginal colpopexy repair with mesh (32 women, 24 anterior mesh, 8 total mesh)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional vaginal colpopexy without mesh (33 women)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vaginal colpopexy repair with mesh
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional vaginal colpopexy without mesh
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vaginal colpopexy repair with mesh and traditional vaginal colpopexy without mesh
Number of subjects: 65
Study: 19090407

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection (5 microg in 0.2 mL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Buffered isotonic saline (control, 0.2 mL)
Number of subjects: 14
Study: 16632022

Group type: EXPERIMENTAL
Intervention: Biofeedback dialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard hemodialysis (HD)
Number of subjects: 8
Study: 14983954

Group type: EXPERIMENTAL
Intervention: Active screening (testing prostate-specific antigen, PSA)
Number of subjects: 10300

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10300
Study: 11058851

Group type: EXPERIMENTAL
Intervention: Radially expanding trocars (group S)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional cutting trocars (group C)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study: 9387731

Group type: EXPERIMENTAL
Intervention: Tangshenkang (TSK) capsule
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 57
Study: 1415946

Group type: EXPERIMENTAL
Intervention: Oral examination performance (grouped as honors, high satisfactory, satisfactory, unsatisfactory)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral examination groups throughout the rotations
Number of subjects: 0
Study: 2991478

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus methanol extractable residue of BCG (MER-BCG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No MER-BCG
Number of subjects: 0
Study: 31211392

Group type: EXPERIMENTAL
Intervention: Morning (fasting) resistance exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Afternoon resistance exercise
Number of subjects: 12
Study: 30010061

Group type: EXPERIMENTAL
Intervention: Colistin monotherapy (loading dose of 9 MIU followed by 3 MIU every 8 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Colistin + meropenem combination therapy (colistin 8.58 MIU and meropenem 1 g every 8 hours for 15 days)
Number of subjects: 60
Study: 26234801

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy (CBT)
Number of subjects: 58
Study: 23829297

Group type: EXPERIMENTAL
Intervention: Multispecies probiotics (Bifidobacterium longum, B. bifidum, B. lactis, Lactobacillus acidophilus, L. rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo twice a day for 4 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Multispecies probiotics
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 22545019

Group type: EXPERIMENTAL
Intervention: Stand-alone lateral interbody fusion
Number of subjects: 52
Study: 20577119

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 9309

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 9309

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 9309

Group type: EXPERIMENTAL
Intervention: ACE I/D polymorphism (rs1799752)
Number of subjects: 9309

Group type: EXPERIMENTAL
Intervention: ACE promoter polymorphism (‐262, rs4291)
Number of subjects: 9309

Group type: EXPERIMENTAL
Intervention: SCNN1A (rs2228576)
Number of subjects: 9309
Study: 17392658

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 15604119

Group type: EXPERIMENTAL
Intervention: Program participants
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study: 11851788

Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Guided relaxation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 9656503

Group type: EXPERIMENTAL
Intervention: Doula support
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lamaze preparation
Number of subjects: 35
Study: 7625503

Group type: EXPERIMENTAL
Intervention: Spermicidal foam
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Spermicidal suppositories
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Foaming tablets
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (no spermicide use)
Number of subjects: 264
Study: 2551622

Group type: EXPERIMENTAL
Intervention: Dilevalol (400 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 321184

Group type: EXPERIMENTAL
Intervention: oxpentifylline (200 mg 3-times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 31812289

Group type: EXPERIMENTAL
Intervention: Liver resection (LR)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Chemotherapy (CTx)
Number of subjects: 154
Study: 30852939

Group type: EXPERIMENTAL
Intervention: MEDI7510 (adjuvanted RSV sF vaccine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 27567020

Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System (OAS) treatment in patients with eGFR < 90 ml/min/1.73 m2
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System (OAS) treatment in patients with eGFR ≥ 90 ml/min/1.73 m2
Number of subjects: 443
Study: 24961535

Group type: EXPERIMENTAL
Intervention: Titanium abutments and porcelain-fused-to-metal crowns
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Zirconia abutments and ceramic crowns
Number of subjects: 11

Group type: COMPARATOR
Intervention: Gingiva of the neighbouring teeth
Number of subjects: 11
Study: 23547848

Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg (s.c.)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tocilizumab 81 mg (s.c.)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tocilizumab (i.v.)
Number of subjects: 48
Study: 21736720

Group type: EXPERIMENTAL
Intervention: Stepped care program (watchful waiting, guided self‐help, short face‐to‐face problem solving treatment, pharmacotherapy and/or specialized mental health care)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 120
Study: 19857803

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT colonography (CECTC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Endoscopic colonoscopy (EC)
Number of subjects: 29
Study: 16670248

Group type: EXPERIMENTAL
Intervention: Alzheimer disease (AD) patients
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cognitively impaired nondemented (CIND) individuals
Number of subjects: 163

Group type: COMPARATOR
Intervention: Total NPI scores
Number of subjects: 163

Group type: COMPARATOR
Intervention: Apathy
Number of subjects: 163
Study: 15048550

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 11
Study: 10986540

Group type: EXPERIMENTAL
Intervention: ACE chemotherapy plus G‐CSF (granulocyte colony‐stimulating factor) at 2‐week intervals
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE chemotherapy alone at standard 3‐week intervals
Number of subjects: 0
Study: 9076616

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg) three times daily for 4 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo three times daily for 4 weeks
Number of subjects: 104
Study: 8401051

Group type: EXPERIMENTAL
Intervention: Trimethylamine oral challenge (600 mg)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Biochemical tests for trimethylamine and trimethylamine N‐oxide
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Psychosocial assessment
Number of subjects: 187
Study: 3533243

Group type: EXPERIMENTAL
Intervention: Blood culture obtained (67 children)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No blood culture obtained (79 children)
Number of subjects: 146
Study: 3045026

Group type: EXPERIMENTAL
Intervention: Defibrotide (200 mg/day, intramuscular)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 20
Study: 30928117

Group type: EXPERIMENTAL
Intervention: Sleep Health Composite score
Number of subjects: 176
Study: 28377492

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening for lung cancer, annual invitation for 4 years
Number of subjects: 3206

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening for lung cancer
Number of subjects: 3206

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3206
Study: 25588664

Group type: EXPERIMENTAL
Intervention: Arm tourniquet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Forearm tourniquet
Number of subjects: 100
Study: 23715925

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g intravenously 15-45 min before skin incision
Number of subjects: 874

Group type: COMPARATOR
Intervention: Ceftriaxone after cord clamping
Number of subjects: 874
Study: 22196238

Group type: EXPERIMENTAL
Intervention: APACHE‐II score on day 1
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: SOFA score on day 2
Number of subjects: 221
Study: 18395725

Group type: EXPERIMENTAL
Intervention: Presacral neurectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uterine nerve ablation
Number of subjects: 0
Study: 17056359

Group type: EXPERIMENTAL
Intervention: AcrySofIQ IOL
Number of subjects: 120

Group type: COMPARATOR
Intervention: AcrySofNatural IOL
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 120
Study: 12604972

Group type: EXPERIMENTAL
Intervention: New infant formula (NF)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 154
Study: 11050580

Group type: EXPERIMENTAL
Intervention: Isotretinoin (1 mg/kg) + Vitamin E (800 IU/day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Isotretinoin (1 mg/kg) + Vitamin E placebo
Number of subjects: 140
Study: 9148645

Group type: EXPERIMENTAL
Intervention: Evastin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Azelastin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 56
Study: 8265524

Group type: COMPARATOR
Intervention: Erythromycin with triazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Roxithromycin with triazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin with midazolam 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 10 mg with erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 10 mg with roxithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 15 mg
Number of subjects: 0
Study: 2872056

Group type: EXPERIMENTAL
Intervention: diacetolol 600 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: acebutolol 400 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: metoprolol 200 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: propranolol 80 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 30462720

Group type: COMPARATOR
Intervention: Insulin resistance (IR)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Normoglycemic (CTRL)
Number of subjects: 106
Study: 26839716

Group type: EXPERIMENTAL
Intervention: Functional Rehabilitation (FS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonfunctional Rehabilitation (NFS)
Number of subjects: 12
Study: 25397825

Group type: EXPERIMENTAL
Intervention: Acupuncture (8 sessions of 60 minutes each, twice weekly)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual PTSD care (UPC)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 55
Study: 22915053

Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m² on days 1-5) and Bevacizumab (10 mg/kg on days 1 and 15) every 28 days (Regimen TB)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Nab-paclitaxel (100 mg/m² or 80 mg/m² post-addendum on days 1, 8, and 15), Bevacizumab (10 mg/kg on days 1 and 15), and Carboplatin (AUC 6 on day 1 or AUC 5 post-addendum) every 28 days (Regimen ABC)
Number of subjects: 93
Study: 20860546

Group type: EXPERIMENTAL
Intervention: ABX‐IL8 (fully human IgG₂ monoclonal antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0